All companies
Visit website
NeXtGen Biologics ™
OperatingNeXtGen Biologics, INC
Healthcare · Biotech · Founded 2023
Woman-founded
Patented, FDA-cleared, novel wound-care technology | new skin in the game
Valuation cap ⓘ
$40.0M
As of Mar 2023 · from NeXtGen Biologics Crowd SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$238,610
Across 1 round since 2022
Latest share price
$1.00
NeXtGen Biologics Crowd SAFE 1 offering price
Financials
FY2020–FY2023 · from SEC filings · hover any figure for its source$0
−$791K
2020
$0
−$2.5M
2021
$184K
−$1.7M
2022
$0
−$2.5M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
Income statement
Revenue
$0
$0
$183,814
$0
Cost of goods sold
$0
$0
$0
$0
Gross margin
—
—
100%
—
Net income
-$790,983
-$2,538,610
-$1,710,186
-$2,538,610
Taxes paid
$51,772
$0
$0
$0
Balance sheet
Cash
$516,897
$247,959
$488,382
$247,959
Accounts receivable
$0
$0
$134,214
$0
Total assets
$2,069,171
$1,926,991
$1,969,512
$1,926,991
Short-term debt
$9,110,917
$10,323,083
$1,189,767
$10,323,083
Long-term debt
$155,400
$3,165,969
$9,960,241
$3,165,969
Total liabilities
$9,266,317
$13,489,052
$11,150,008
$13,489,052
Other
Headcount
—
9
10
10
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$40.0M
Valuation cap
NeXtGen Biologics Crowd SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $238.6K / $5MInvestors 347Valuation cap $40M
Reg CF annual-report compliance
Delinquent
Filed 1 of 4 annual reports (FY2022–FY2025)
Missing: 2022, 2024, 2025
347 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 11 filings on EDGARSource: ManualCIK 0001620524Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.